Short traders are more bearish on Endologix Inc considering the increase in short interest. The stock recorded a rise in short interest of 8.19% as of October 13, 2017 from the last reporting period. Short interest grew from 13,525,718 to 14,633,812 over that period. The days to cover decreased to 12.0 and the short interest percentage is 0.18% as of October 13.
Here are a few substantial investment firms who have updated their positions. As of the end of the quarter American International Group Inc had acquired a total of 4,122 shares growing its holdings by 8.1%. The value of the investment in ELGX went from $248,000 to $246,000 a change of 0.8% quarter to quarter. Citigroup Inc divested its position by selling 2,361 shares a decrease of 80.9%. Citigroup Inc owns 557 shares with a value of $2,000. The value of the position overall is down by 85.7%.
As of quarter end Wellington Management Group Llp had bought 50 shares growing its stake by 0.6%. The value of the investment in (ELGX) decreased from $43,000 to $39,000 a change of $4,000 since the last quarter. California State Teachers Retirement System reduced its ownership by shedding 12,403 shares a decrease of 8.5% in the quarter. California State Teachers Retirement System controls 133,282 shares worth $594,000. The total value of its holdings decreased 16.1%.
Royal Bank Of Canada lowered the price target on November 8 changing the forecast from $5.00 to $4.00 with a “Sector Perform” recommendation. November 8 investment analysts at Canaccord Genuity left the company rating at “Hold” with a current price target of $5.00.
Equity analyst Stifel Nicolaus lowered the price target on November 8 changing the price objective from $6.00 to $5.50 and issued a “Hold” rating. On October 9 Canaccord Genuity kept the company rating at “Hold” targeting a price of $5.00.
Stifel Nicolaus released a research note on ELGX with a rating of “Hold” and projecting a price target of $6.00. On October 3 Royal Bank Of Canada maintained a stock rating of “Hold” projecting a price of $5.00.
The company is now up since yesterday’s close of 4.98. The company’s P/E ratio is N/A and market cap is 427.70M. As of the last earnings report the EPS was $-0.93 with 83.45M shares now outstanding.
Endologix, Inc., launched on June 2, 1993, is involved in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Business’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). Sales of the Business’s EVAR and EVAS platforms (including extensions and accessories) to hospitals in the United States and Europe, and to third-party international distributors provide the sole source of its revenue. It offers various accessories to facilitate the optimal delivery of its EVAR and EVAS products, including compatible guidewires, snares, and catheter introducer sheaths..